Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 12,232 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Diseases Clear all
Recruiting No phase listed Observational

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

NCT06784167
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Primary Mediastinal Large B-Cell Lymphoma, Small Lymphocytic Lymphoma
Interventions
Non-Interventional Study
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 2 Interventional Results available

Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis

NCT00551707
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CRx-102 (2.7/180), prednisolone, dipyridamole, placebo, CRx-102 (2.7/360)
Drug
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 3 Interventional Results available

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

NCT02171130
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
Interventions
Nasal Glucagon
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Waltham, Massachusetts • Minneapolis, Minnesota • Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Nov 11, 2026, 11:38 PM EST
Completed No phase listed Observational

10003 PRO Current Products

NCT01497730
View directory record Official record
Conditions
Osteoarthritis
Interventions
Total Knee Replacement
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
22 Years to 80 Years
Enrollment
842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
11
States / cities
Orange, California • San Diego, California • Fort Collins, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Nov 11, 2026, 11:38 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

NCT03203330
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 11, 2026, 11:38 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alefacept in Patients With Severe Scalp Alopecia Areata

NCT00167102
View directory record Official record
Conditions
Alopecia Areata
Interventions
Alefacept
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 1 Interventional

Study of NGM621 in Participants With Geographic Atrophy

NCT04014777
View directory record Official record
Conditions
Geographic Atrophy
Interventions
NGM621
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Arcadia, California • Newport Beach, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

NCT02343458
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
44
States / cities
Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Nov 11, 2026, 11:38 PM EST
Completed No phase listed Observational

Myeloperoxidase and Multi-Markers In the Diagnosis of Diagnoses of Acute Coronary Syndrome (MIDAS) - Sample Procurement

NCT00415948
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
Biomarkers
Device
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Sacramento, California • New Haven, Connecticut • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2009 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 2 Interventional

Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

NCT01111955
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BMS-823778, Placebo, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Hialeah, Florida • Olympia, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Nov 11, 2026, 11:38 PM EST
Terminated Phase 2 Interventional Results available

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

NCT03087058
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Palo Alto, California • Kansas City, Kansas • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Nov 11, 2026, 11:38 PM EST
Recruiting Not applicable Interventional

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

NCT03184038
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Interventions
Cognitive Assessment, Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Sewell, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 11, 2026, 11:38 PM EST
Terminated Phase 2 Interventional

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
View directory record Official record
Conditions
PAH
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Nov 11, 2026, 11:38 PM EST
Recruiting Phase 1Phase 2 Interventional

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

NCT04879043
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Disorder
Interventions
HDP-101
Drug
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 11, 2026, 11:38 PM EST
Completed No phase listed Observational Accepts healthy volunteers

MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis

NCT02845635
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Personal history of multiple sclerosis
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Nov 11, 2026, 11:38 PM EST
Completed No phase listed Observational

Patient Communication Training Intervention

NCT00933855
View directory record Official record
Conditions
Cancer
Interventions
Questionnaires and training workshop
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 2 Interventional Results available

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

NCT00790647
View directory record Official record
Conditions
Multiple Myeloma
Interventions
filgrastim, bortezomib, melphalan, Stem Cell Infusion
Biological · Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 2 Interventional Results available

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

NCT00538733
View directory record Official record
Conditions
Multiple Myeloma
Interventions
thalomid, lenalidomide, clarithromycin, dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Nov 11, 2026, 11:38 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts

NCT06856148
View directory record Official record
Conditions
Substance Abuse, Substance Use Disorders, Prevention, Legislation, Use of Research Evidence
Interventions
Intervention: RPC Group, Active Comparator: Control Group
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 1 Interventional

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

NCT00762255
View directory record Official record
Conditions
Glioblastoma
Interventions
Vorinostat, Bevacizumab, Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Nov 11, 2026, 11:38 PM EST
Completed No phase listed Observational

Teriflunomide Male Transmission Study

NCT02679885
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Nov 11, 2026, 11:38 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

NCT03933735
View directory record Official record
Conditions
Multiple Myeloma
Interventions
TNB-383B
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
San Francisco, California • New Orleans, Louisiana • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 1 Interventional

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

NCT02202226
View directory record Official record
Conditions
Schizophrenia
Interventions
Lu AF35700, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Nov 11, 2026, 11:38 PM EST
Completed Phase 3 Interventional Results available

A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT00505778
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine Once-Daily, Mesalamine Twice-Daily
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
233
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Nov 11, 2026, 11:38 PM EST